This is an afterword to the JME symposium on the benefit/risk ratio challenge in clinical research, and the case of HIV cure. It notes implications of the symposium for research ethics in general.
- HIV Infection and AIDS
- Research Ethics
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding This work was funded by NIAID grants 1 R01 AI114617-01A1 and 1 R56 AI114617-01, both titled ‘HIV cure studies: risk, risk perception, and ethics’. The study sponsor had no role in the study design; in the collection, analysis and interpretation of the data; in the writing of the report and in the decision to submit the paper for publication.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- How to keep high-risk studies ethical: classifying candidate solutions
- Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment
- Ethics of vaccine refusal
- Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy
- The Gettier Problem in informed consent
- Beyond informed consent: the therapeutic misconception and trust
- The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction
- Nudge me, help my baby: on other-regarding nudges
- The morality of risks in research: reflections on Kumar
- Streamlining the Clinical Research Enterprise